SCHEMBL6093940

SCHEMBL6093940

CCOC(=O)c1nc(N)n(C)c(=O)c1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 4/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ADORA2A P29274 4/20 0.44
ADORA1 P30542 2/20 0.44
ADORA3 P0DMS8 1/20 0.44
ADORA2B P29275 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MAPT P10636 4/20 0.43
MAOB P27338 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15455511 0.88 HPGD (0.51) KDM4EALDH1A1HPGDHSD17B10ADORA2A
SCHEMBL3416727 0.88 KMT2A (0.46) KDM4EALDH1A1HPGDMAOBMEN1
SCHEMBL2512337 0.84 HPGD (0.47) KDM4EHPGDADORA2AADORA1ADORA3
SCHEMBL6093491 0.84 KDM4E (0.44) KDM4EALDH1A1HPGDADORA2AADORA1
SCHEMBL6093718 0.84 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10ADORA2A
SCHEMBL2510778 0.81 ADORA3 (0.44) KDM4EALDH1A1ADORA3SMN1; SMN2TSHR
SCHEMBL6094142 0.80 SMN1; SMN2 (0.40) KDM4EALDH1A1HPGDHSD17B10ADORA2A
SCHEMBL6093130 0.80 KDM4E (0.39) KDM4EALDH1A1HPGDHSD17B10ADORA2A
SCHEMBL6095402 0.79 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10ADORA2A
SCHEMBL6086680 0.79 ALDH1A1 (0.41) KDM4EALDH1A1NPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US disclosed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed
WO-2004062613-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204498-A1 HIV integrase inhibitors IMPDH1, TYMP, REV1 KDM4E 1484/4885ALDH1A1 483/4885HPGD 2482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.